

**EFFECTIVE DATE:** 09|01|2019

**POLICY LAST UPDATED:** 05|07|2019

## OVERVIEW

Elzonris™ (tagraxofusp-erzs) is for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients 2 years and older.

This policy is applicable to BlueCHiP for Medicare products only. For Commercial Products, see related policy section.

## MEDICAL CRITERIA

Elzonris™ (tagraxofusp-erzs) will be approved when ALL of the following are met:

1. ONE of the following:

A. There is documentation the patient is currently being treated with the requested agent

**OR**

B. The prescriber states the patient is currently being treated with the requested agent AND is at risk if therapy is changed

**OR**

C. The patient has an FDA labeled indication for the requested agent AND ALL of the following:

i. ONE of the following:

1. The requested indication does NOT require genetic/specific diagnostic testing (e.g., ALK, EGFR, HER2, KRAS) in FDA labeling

**OR**

2. The requested indication requires genetic/specific diagnostic testing in the FDA labeling AND ONE of the following:

a. BOTH of the following

i. Genetic/diagnostic testing has been performed

**AND**

ii. The results of the genetic/diagnostic testing indicate therapy with the requested agent is appropriate

**OR**

b. The requested indication does not require genetic/specific diagnostic testing in NCCN with level of evidence 1 or 2a

**AND**

ii. ONE of the following:

1. The requested agent is FDA labeled as a first-line agent for the requested indication

**OR**

2. The patient has used the appropriate number and type(s) of prerequisite agent(s) listed in the FDA labeling for the requested indication

**OR**

3. The patient has used the appropriate number and type(s) of prerequisite agent(s) supported by NCCN 1 or 2A recommended use for the requested indication

**OR**

4. The patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to ALL of the required prerequisite agent(s) listed in the FDA labeling for the requested indication

**AND**

iii. ONE of the following:

1. The requested agent is approved for use as monotherapy in the FDA labeling for the requested indication

**OR**

2. The requested agent will be used with all agent(s) and/or treatments (e.g., radiation) listed for concomitant use in the FDA labeling for the requested indication

**OR**

3. The requested agent will be used with all agent(s) and/or treatments supported in NCCN 1 or 2a recommended use for the requested indication

**AND**

iv. ONE of the following:

1. The FDA label does NOT include a performance status requirement

**OR**

2. The patient meets the performance status requirement in the FDA labeling

**OR**

D. The patient has an NCCN 1 or 2A recommended indication [i.e., this indication must be supported by ALL requirements in the NCCN “Recommended Use” box (e.g., performance status, disease severity, previous failures, monotherapy vs combination therapy, etc.)]

**AND**

2. The patient does NOT have any FDA labeled contraindications to the requested agent

**AND**

3. The requested dose and duration is within FDA labeling or NCCN 1 or 2A compendia supported dosing for the requested indication

**Length of Approval:** 12 months or for duration of treatment as supported in FDA labeling or in NCCN 1 or 2a recommendations for the requested indication, whichever is shorter.

### **PRIOR AUTHORIZATION**

Prior authorization is required for BlueCHiP for Medicare.

### **POLICY STATEMENT**

#### **BlueCHiP for Medicare**

Elzonris™ (tagraxofusp-erzs) is medically necessary when the criteria above have been met.

### **COVERAGE**

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable physician administered drug medically necessary benefits/coverage.

### **BACKGROUND**

Elzonris (tagraxofusp-erzs), a CD123-directed cytotoxin, is a fusion protein comprised of a recombinant human interleukin-3 (IL-3) and truncated diphtheria toxin (DT) that inhibits protein synthesis and causes cell death in CD123-expressing cells.

### **CODING**

#### **BlueCHiP for Medicare**

The following HCPCS code is covered when the medical criteria have been met:

**C9049** Injection, tagraxofusp-erzs, 10 mcg

## RELATED POLICIES

Prior Authorization of Drugs

## PUBLISHED

Provider Update, July 2019

## REFERENCES

1. Elzonris Prescribing Information. Stemline Therapeutics Inc. December 2018.

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

